Novel Therapies

In May 2019, ACCC and SITC hosted a by-invitation Joint Immuno-Oncology Policy Summit in Washington, D.C. The interdisciplinary discussion focused on next steps in advancing immunotherapy for cancer with a focus on three areas: telehealth, CAR T implications, and care coordination and workforce issues. In this video, summit participants Sarah Murawski, MPAS, PA-C, Hematology/Oncology, Stem Cell Transplant, Cellular Therapy Nocturnist, Vanderbilt Ingram Cancer Center, and Robert Richards, MBA, Administrative Director, Cell Therapy and Transplant, Penn Medicine, UPenn Health System, talk about the future of CAR-T therapy, the need for adequate reimbursement for CAR T, and the potential role telehealth may play in expanding access to this promising new therapy.


The Latest Resources

  • COVID-19 and Patients Receiving Anticancer Immunotherapy
    COVID-19 and Patients Receiving Anticancer Immunotherapy
    By Ryan M. Weight, DO, MS

    SARS-CoV-2 and the resulting respiratory tract infection COVID-19 has upended our society and forcefully changed the way we care for patients. Since the emergence of the virus in early 2020, there have been questions surrounding the risk posed to patients with a cancer diagnosis and the safety of anticancer therapies. 

  • [Publication] Immuno-Oncology in 2020: What We’ve Learned and What Lies Ahead
    In this newly published IO Whitepaper, we take a forward look at how the ACCC IO Institute meets the needs of the evolving multidisciplinary cancer care team and other interdisciplinary providers who may be involved in caring for patients treated with immunotherapies for cancer.
  • The Oncology Pharmacist's Role in IO Delivery
    By Sarah Hudson-DiSalle, PharmD, RPh

    Are you leveraging the assets of your oncology pharmacists in delivery of immunotherapy for cancer? Oncology pharmacists multidisciplinary team members who help bridge the gap between science and real-world medical practice. Sarah Hudson-DiSalle, PharmD, RPh, describes how your IO program can make the best use of the oncology pharmacist's diverse skillset.  

  • Virtual Navigation to Clinical Trials
    By Jennifer C. King, PhD

    In the current oncology clinical trials landscape, many barriers remain to clinical trial enrollment that affect both the oncologist and the patient. Among these are trial locations, strict eligibility requirements, insufficient resources to support appropriate clinical trial education and screening, as well as patient and provider attitudes about trials.

From Oncology Issues

On-Demand Webinars

  • Learn how the microbiome could potentially be used to predict and enhance response to I-O therapy and to recognize patients who could be at risk for developing immune-related adverse events.


  • Expanding Access to Bispecific Antibodies in Community Cancer Care
    August 03, 2022
    Learn how ACCC's bispecific antibody initiative “Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management”—developed in partnership with the Society for Immunotherapy of Cancer—will help expand the use of these novel therapies and optimize care for patients with cancer.
  • Micro Inmunoterapia_ACCCBuzz
    ACCC Tools for Immuno-Oncology Survivorship Care
    June 03, 2022
    In recognizing Cancer Immunotherapy Month and National Cancer Survivors Day (June 5), ACCC is highlighting the resources it has created to assist the multidisciplinary team in creating and adapting survivorship care plans to meet these patients’ unique needs and support toxicity management for better outcomes.
    The Best (and Worst) of 2020
    December 30, 2020
  • Sigrun Hallmeyer pic
    June Is Cancer Immunotherapy Month
    June 25, 2020
    In recognition of Cancer Immunotherapy Month, ACCCBuzz talked to Sigrun Hallmeyer, MD, the chair of the ACCC Immuno-Oncology Institute’s Executive Committee.